Abstract: The heart failure with preserved left ventricular ejection fraction(HFpEF) has become the main form of heart failure, nearly half of the population suffering from heart failure. With medical diagnosis and treatment technology widely used, and prolonged life expectancy, the incidence rate is increasing. At present, HFpEF is getting more and more attention. As a basic drug for heart failure, β-blockers are widely used in clinical practice. But it's use of HFpEF, the current results are not satisfactory. This article describes the mechanism and current status of β-blockers in the treatment of HFpEF. Combined with existing clinical evidence, it also provides direction for future clinical research.